On December 2, 2024, Hemerion presented its Pentalafen/Heliance technology at the CHU x Healtech Connection Day event, which brings together hospital professionals and healthcare entrepreneurs.
The “CHU X HealthTech Connection Day”, whose third edition took place on December 2, 2024 at the Lille Grand Palais, is a key event for healthcare innovation in France. Co-organized by France Biotech and the Conférence des Directeurs Généraux de CHU, it brings together entrepreneurs and hospital staff to strengthen collaboration between the hospital-university world and the HealthTech industry, and to promote therapeutic innovation.
Hemerion was invited to present its Pentalafen/Heliance technology at the 2024 event and to share its experience of working with Lille University Hospital.
The Heliance technology was first developed by a research unit at INSERM, the University of Lille and the Lille University Hospital, which hosted the first two clinical trials dedicated to this technology. These trials were conducted directly between 2018 and 2022 by Pr. Nicolas Reyns, co-inventor of the technology and neurosurgeon.
Maximilien Vermandel also took part in the round table “Impacts and benefits of innovation in health care institutions”, moderated by Frédéric Girard (France Biotech) and Florence Favrel Feuillade (University Hospital of Brest), with Régis Bordet (Lille University), Armelle Dion, Lyon University Hospital, Charles Édouard Escurat, French Health Innovation Agency, Arnaud Mascarell, FineHeart, Arnaud Pouillart, Angers University Hospital & HUGO Network and David Sainati, French Digital Health Agency.
